Literature DB >> 28154257

Antibody Fragments for On-Site Testing of Cannabinoids Generated via in Vitro Affinity Maturation.

Izumi Morita1, Hiroyuki Oyama, Mayumi Yasuo, Kazuhisa Matsuda, Kengo Katagi, Aya Ito, Hiroka Tatsuda, Hiroyuki Tanaka, Satoshi Morimoto, Norihiro Kobayashi.   

Abstract

Law enforcement against illicit use of cannabis and related substances requires rapid, feasible, and reliable tools for on-site testing of cannabinoids. Notably, methods based on cannabinoid-specific antibodies enable efficient screening of multiple specimens. Antibody engineering may accelerate development of modern and robust testing systems. Here, we used in vitro affinity maturation to generate a single-chain Fv fragment (scFv) that recognizes with high affinity the psychoactive cannabinoid, Δ9-tetrahydrocannabinol (THC). A mouse monoclonal antibody against THC, Ab-THC#33, with Ka 6.2×107 M-1 (as Fab fragment) was established by the hybridoma technique. Then, a "wild-type" scFv (wt-scFv) with Ka, 1.1×107 M-1 was prepared by bacterial expression of a fusion gene combining the VH and VL genes for Ab-THC#33. Subsequently, random point mutations in VH and VL were generated separately, and the resulting products were assembled into mutant scFv genes, which were then phage-displayed. Repeated panning identified a mutant scFv (scFv#m1-36) with 10-fold enhanced affinity (Ka 1.1×108 M-1) for THC, in which only a single conservative substitution (Ser50Thr) was present at the N-terminus of the VH-complementarity-determining region 2 (CDR2) sequence. In competitive enzyme-linked immunosorbent assay (ELISA), the mutant scFv generated dose-response curves with midpoint 0.27 ng/assay THC, which was 3-fold lower than that of wt-scFv. Even higher reactivity with a major THC metabolite, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, indicated that the mutant scFv will be useful for testing not only THC in confiscated materials, but also the metabolite in urine. Indeed, the antibody fragment is potentially suitable for use in advanced on-site testing platforms for cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28154257     DOI: 10.1248/bpb.b16-00669

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

Review 1.  Monoclonal Antibodies Application in Lateral Flow Immunochromatographic Assays for Drugs of Abuse Detection.

Authors:  Zidane Qriouet; Yahia Cherrah; Hassan Sefrioui; Zineb Qmichou
Journal:  Molecules       Date:  2021-02-18       Impact factor: 4.411

2.  The VH framework region 1 as a target of efficient mutagenesis for generating a variety of affinity-matured scFv mutants.

Authors:  Yuki Kiguchi; Hiroyuki Oyama; Izumi Morita; Yasuhiro Nagata; Naoko Umezawa; Norihiro Kobayashi
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

3.  Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method.

Authors:  Hideaki Sanada; Kazuki Kobayashi; Kenji Oyama; Takamitsu Maru; Takeshi Nakanishi; Mitsuo Umetsu; Ryutaro Asano; Izumi Kumagai
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

4.  Clonal array profiling of scFv-displaying phages for high-throughput discovery of affinity-matured antibody mutants.

Authors:  Yuki Kiguchi; Hiroyuki Oyama; Izumi Morita; Mai Morikawa; Asuka Nakano; Wakana Fujihara; Yukari Inoue; Megumi Sasaki; Yuki Saijo; Yuki Kanemoto; Kaho Murayama; Yuki Baba; Atsuko Takeuchi; Norihiro Kobayashi
Journal:  Sci Rep       Date:  2020-08-24       Impact factor: 4.379

5.  Seeking high-priority mutations enabling successful antibody-breeding: systematic analysis of a mutant that gained over 100-fold enhanced affinity.

Authors:  Hiroyuki Oyama; Yuki Kiguchi; Izumi Morita; Chika Yamamoto; Yuka Higashi; Miku Taguchi; Tatsuya Tagawa; Yuri Enami; Yuriko Takamine; Hanako Hasegawa; Atsuko Takeuchi; Norihiro Kobayashi
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.